Literature DB >> 16103771

Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.

Raghavan Chinnadurai1, Jan Münch, Frank Kirchhoff.   

Abstract

BACKGROUND: Sequence variations in the gp41 heptad repeat 1 (HR1) region have been identified in some treatment-naive HIV-1-infected patients but it remained elusive whether they confer resistance to fusion inhibitors.
OBJECTIVE: To evaluate whether naturally occurring sequence variations in the HIV-1 group M gp41 HR1 region affect the sensitivity to inhibition by T-20 and T-1249.
METHODS: Site-directed mutagenesis was used to generate HIV-1 NL4-3 mutants containing changes in the gp41 HR1 domain which have been previously identified in treatment-naive patients infected with various HIV-1 group M subtypes. HIV-1 variants were produced by transient transfection of 293T cells and used to determine viral infectivity and sensitivity to the fusion inhibitors T-20 and T-1249.
RESULTS: Most naturally occurring sequence variations in the HR1 domain did not reduce viral infectivity. Three of the 10 HIV-1 variants analysed containing a single substitution of L33V, which is frequently present in subtype D isolates, or combined changes of L54M/Q56K or L34M/L54M/Q56R showed about fivefold reduced sensitivity to inhibition by T-20. In comparison, none of these HR1 sequence variations conferred resistance to T-1249.
CONCLUSION: Some naturally occurring sequence variations in the gp41 HR1 region reduce sensitivity of HIV-1 to inhibition by T-20 but not T-1249.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103771     DOI: 10.1097/01.aids.0000180785.25800.de

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Yuxian He; Sheng Cui
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

2.  Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-01-06       Impact factor: 5.157

3.  Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.

Authors:  Dirk Eggink; Johannes P M Langedijk; Alexandre M J J Bonvin; Yiqun Deng; Min Lu; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2009-07-17       Impact factor: 5.157

4.  Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.

Authors:  Raghavan Chinnadurai; Devi Rajan; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

5.  Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.

Authors:  Nália Ismael; Dulce Bila; Diana Mariani; Adolfo Vubil; Nedio Mabunda; Celina Abreu; Ilesh Jani; Amilcar Tanuri
Journal:  AIDS Res Hum Retroviruses       Date:  2013-12-21       Impact factor: 2.205

6.  Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.

Authors:  Huihui Chong; Xue Yao; Chao Zhang; Lifeng Cai; Sheng Cui; Youchun Wang; Yuxian He
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.